The FDA granted Breakthrough Device designation to Natera's cell-free DNA multi-cancer early detection assay. What it means for primary care.
The US Food and Drug Administration (FDA) has granted Breakthrough Device designation to Natera's multi-cancer early detection (MCED) assay, a blood-based test that analyzes cell-free DNA to screen for multiple cancers, the company announced October 9, 2026.<sup>1</sup>
The designation is intended to speed development and review of the investigational assay. It does not constitute FDA approval, clearance, or marketing authorization.<sup>2</sup>
According to Natera, the FDA assessed data across 12 cancer types in granting the designation.<sup>1</sup> The agency considered the assay's sensitivity, specificity, and cancer signal origin (CSO) performance, which refers to the test's ability to predict where in the body a detected cancer signal originates.<sup>1</sup>
Natera described the results as supporting the designation but did not disclose specific performance figures or name the 12 cancer types in its announcement.<sup>1</sup>
"Too many cancers are diagnosed after they've progressed," said Alexey Aleshin, MD, Natera's corporate chief medical officer and general manager of oncology and early cancer detection, who attributed the problem to limited screening options.<sup>1</sup> Aleshin said the company plans to work with the FDA toward its goal of detecting cancer at earlier, more treatable stages.1
For primary care physicians, the designation signals continued regulatory momentum for blood-based MCED testing but does not change what is available to offer your patients today. The assay has not been cleared or approved by the FDA, and the performance data behind the designation have not been made public.1,2
Clinicians whose patients ask about MCED blood tests can explain that this assay remains investigational and that its accuracy, including false-positive rates and its ability to localize cancers, will be evaluated as it moves through FDA review.1,2
